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K+ channel mutations in  
primary hyperaldosteronism
Choi et al., Science 2011; 331: 768–772; doi:10.1126/science.1198785
Adrenal adenomas that secrete aldosterone in an unregulated man-
ner have been recognized as a cause of hypertension since Conn’s 
description of patients with the syndrome more than 50 years ago. 
In these patients, aldosterone-mediated sodium retention induces 
extracellular fluid expansion that, in turn, causes hypertension and 
inhibition of renin secretion. Hence, the combination of an ele-
vated plasma aldosterone with a low plasma renin in a patient with 
hypertension is the hallmark of the disease. Despite much study, 
however, the mechanisms responsible for the proliferation of the 
adrenal cells causing the tumor and their secreting aldosterone have 
remained unclear. Under normal conditions, aldosterone is pro-
duced by the adrenal glomerulosa cells in response to extracellular 
volume depletion via angiotensin II or in response to hyperkale-
mia. As in many secretory cells, the resting membrane potential 
of the adrenal glomerulosa cells is set by K+ channel activity, and 
both angiotensin II signaling and hyperkalemia induce membrane 
depolarization and subsequent activation of voltage-gated Ca2+ 
channels. The resulting increase in intracellular Ca2+ provides the 
signal for aldosterone production, and sustained increases lead to 
glomerulosa-cell proliferation. In a recent study, Choi et al. stud-
ied 22 patients with adrenal adenomas with hypertension, high 
aldosterone–renin ratios, and unilateral adrenal cortical mass on 
computed tomography. Adrenocortical tumors were obtained by 
surgery, and the pathology diagnosis confirmed adrenocortical 
adenoma. The authors found two recurrent somatic mutations in 
and near the selectivity filter of the K+ channel KCNJ5 that were 
present in 8 of 22 aldosterone-producing adenomas. Both muta-
tions produced increased Na+ conductance and cell depolariza-
tion, which in the adrenal glomerulosa cells should induce Ca2+ 
entry, the signal for aldosterone production and cell proliferation. 
In addition, they identified an inherited KCNJ5 mutation that pro-
duced increased Na+ conductance in a mendelian form of severe 
aldosteronism and massive bilateral adrenal hyperplasia. These 
findings implicate inherited and acquired mutations in KCNJ5 in 
aldosteronism associated with cell-autonomous proliferation; the 
very small number of somatic mutations found, the young age of 
most subjects with KCNJ5 mutations, and mendelian transmission 
of the inherited syndrome are consistent with the KCNJ5 muta-
tions’ being sufficient for both constitutive aldosterone secretion 
and cell proliferation. As shown in the figure, the increased Na+ 
conductance and membrane depolarization resulting from these 
mutations implicate activation of voltage-gated Ca2+ channels in 
the mechanism of cell proliferation and aldosterone production. 
Thus, these findings explain pathogenesis in a subset of patients 
with severe hypertension and implicate loss of K+ channel selectiv-
ity in constitutive cell proliferation and hormone production.
Juan Oliver
Naturally occurring higher 
hemoglobin concentration does 
not increase mortality among 
hemodialysis patients
Goodkin et al., J Am Soc Nephrol 2011; 22: 358–365; doi:10.1681/
ASN.2010020173
Clinical trials in anemia management among patients with 
chronic kidney disease and end-stage renal disease (ESRD) dem-
onstrate that targeting a higher hemoglobin concentration causes 
an increased risk of cardiovascular outcomes, including death.1–3 
Observational data as well as the trials themselves demonstrate an 
association between higher hemoglobin and better outcomes,1–4 
suggesting an association between erythropoiesis-stimulating 
agent (ESA) dose and this risk. Goodkin et al. examined the asso-
ciation between hemoglobin and mortality among patients who 
can achieve a higher hemoglobin concentration in the absence 
of ESA therapy. The Dialysis Outcomes and Practice Patterns 
Study is a multinational observational study of almost 30,000 
dialysis patients selected at random, designed to examine the epi-
demiology and outcomes of ESRD worldwide. For this analysis, 
‘endogenous erythropoietin’ patients were defined as those who 
were not receiving ESA treatment when they entered the study or 
during the 4-month study time and had a hemoglobin concentra-
tion greater than 12 g/dl at both times. All other patients were 
classified as ‘other.’ Of the prevalent patients, only 2.3% satisfied 
the definition of an endogenous erythropoietin (EPO) patient. 
The proportion of the population qualifying as endogenous EPO 
varied significantly across countries. Cystic disease was overrep-
resented in this group but in a minority of the population, at 
only about 25%. Patient characteristics associated with a greater 
likelihood of being an endogenous EPO patient included male 
gender, greater ESRD vintage, current smoking, and comorbidi-
ties, such as cardiovascular disease (other than coronary artery 
disease and congestive heart failure), hypertension, and lung 
Proposed mechanism for aldosterone-producing adenoma and 
mendelian aldosteronism. (a) Adrenal glomerulosa cells have a high 
resting K+ conductance, which produces a highly negative membrane 
potential. (b) Membrane depolarization by either elevation of 
extracellular K+ or closure of K+ channels by angiotensin II activates 
voltage-gated Ca2+ channels, increasing intracellular Ca2+ levels, and this 
provides signals for increased aldosterone synthesis and for increased 
cell proliferation. (c) Channels containing KCNJ5 with mutations 
conduct Na+, resulting in Na+ entry, chronic depolarization, constitutive 
aldosterone production, and cell proliferation.
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disease. Laboratory measures associated with a greater likelihood 
included greater body mass index, greater albumin, higher para-
thyroid hormone, and lesser ferritin. The presence of a central 
catheter for dialysis access was less likely in the endogenous EPO 
group. As compared with the other patients in the fully adjusted 
model, endogenous EPO patients did not have a different mor-
tality risk, whether considered overall (relative risk (RR) = 0.98, 
95% confidence interval (CI) 0.80–1.19) or stratified on 10–12 
g/dl or >12 g/dl hemoglobin (RR = 0.94, 95% CI 0.72–1.22, vs. 
RR = 1.03, 95% CI 0.83–1.27, respectively).
Although no cause–effect relationship can be established, this 
study is important because it adds support to the hypothesis that 
poorer outcomes among patients targeted to a higher hemoglobin 
goal in intention-to-treat analyses of anemia trials are perhaps 
related not to the achieved hemoglobin concentration but rather 
to the higher doses required to attempt to achieve the goal.
Lynda Szczech
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Risk HLA-DQA1 and  
PLA2R1 alleles in idiopathic  
membranous nephropathy
Stanescu et al., N Engl J Med 2011; 364: 616–626; doi:10.1056/NEJMoa1009742
Idiopathic membranous nephropathy (IMN) is a major cause of 
the nephrotic syndrome in adults, with a known, but ill-defined, 
relationship to the human leukocyte antigen (HLA) system. 
Recently, antibodies against a receptor for phospholipase A2 
(PLA2R1) have been recognized as contributing to the genera-
tion of IMN. Now, a group of scientists reports results of inde-
pendent genome-wide association studies of single-nucleotide 
polymorphisms in patients with IMN from France, the Nether-
lands, and the United Kingdom. They identified two genomic 
loci strongly associated with IMN: one on chromosome 2q24 
contains the gene encoding the M-type phospholipase A2 recep-
tor (PLA2R1), and one on chromosome 6p21 encompasses the 
HLA complex class II HLA-DQ a-chain 1 (HLA-DQA1). The 
odds ratio for IMN homozygosity for both risk alleles was 78.5 
(95% CI 34.6–178.2), an extremely strong and convincing ratio 
for single-nucleotide polymorphism studies, and supports their 
association with IMN. Furthermore, they fit with the hypothesis 
that IMN represents an autoimmune disease in which the dis-
ease-inducing antibody response is related to the presentation of 
a ‘genetic risk’ epitope such as PLA2R1, by a ‘genetic risk’ HLA-
DQA1 allele. Together, these findings open the way to explore 
how and why these polymorphisms produce an autoimmune 
response that results in IMN under certain circumstances. These 
are prerequisites for the design of much more target-directed and 
specific forms of therapy than are presently available for IMN. 
The international group of researchers ought to be congratulated 
for this wonderful and fruitful collaboration, which lifts the veil 
some more on the mystery of membranous nephropathy.
Detlef Schlöndorff
Inhibition of matrix 
metalloproteinases reduces 
ischemia–reperfusion acute 
kidney injury
Kunugi et al., Lab Invest 2011; 91: 170–180; doi:10.1038/labinvest.2010.174
Matrix metalloproteinases (MMPs), a family of zinc-dependent 
proteases responsible for extracellular matrix turnover, have 
been demonstrated to have major roles in the pathophysiol-
ogy of ischemia–reperfusion injury in several organs, including 
the central nervous system, heart, liver, and lung. The role of 
MMPs during the development of acute kidney injury (AKI) is 
still uncertain, as contradictory results have been reported by 
several studies. Kunugi et al. performed a study in wild-type 
and MMP-2/MMP-9 knockout mice, examining the possible 
role of these gelatinases in the development of ischemic AKI. 
AKI was induced in these mice by 30, 60, 90, and 120 minutes of 
renal ischemia and reperfusion. Renal histology, expression and 
activity of MMP-2 and MMP-9, and renal function were exam-
ined during the development of AKI. AKI was also induced 
in mice treated with inhibitors of MMPs (minocycline and 
synthetic peptide MMP inhibitor). In wild-type mice, MMP-2 
and MMP-9 activities increased significantly at 2–24 hours, 
peaking at 6 hours, after reperfusion. Immunohistochemical 
analysis identified MMP-2 in the interstitium around tubules 
and peritubular capillaries (PTCs) in the outer medulla. Immu-
nohistochemical analysis in the present study demonstrated 
downregulation of TIMP-1 and TIMP-2 (endogenous inhibitors 
of MMPs) at 6 hours after reperfusion. Acute tubular injury 
(ATI), including apoptosis and necrosis, was evident in the 
outer medulla at 24 hours, along with renal dysfunction. As 
the ischemia period increased, MMP-2 and MMP-9 activi-
ties at 6 hours and the severity of AKI at 24 hours increased 
depending on the duration of ischemia between 30 and 120 
minutes. However, the kidneys of MMP-2 knockout mice 
showed minimal ATI; serum creatinine 24 hours after reper-
fusion was significantly low in these mice. Inhibitors of MMPs 
reduced ATI and improved renal dysfunction at 24 hours. The 
ischemia–reperfusion-induced MMP expression is shifting the 
protease–protease inhibitor balance toward proteolytic activity 
and extracellular matrix degradation. Overexpression of MMPs 
mediates the degradation of the basement membrane of PTCs 
and subsequent destruction of PTCs and renal microvascula-
ture injury/interstitial hemorrhage, which could be associated 
with the development of severe AKI.
This work contributes to the better understanding of the role 
of MMPs, especially MMP-2, in ischemia–reperfusion AKI. 
Inhibitors of MMPs can protect against ischemic AKI. Further 
studies examining the role of MMPs in the recovery phase of 
ischemic AKI are mandatory in view of their beneficial effect 
during remodeling/recovery from several diseases and injury 
as described in the recent literature.
Marc De Broe 
